Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Alopecia Areata

Therapeutic area intelligence for Alopecia Areata with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Companies
2

Companies

Eli Lilly →
Sun Pharma →

Assets

deuruxolitinib →
Ritlecitinib →
Ruxolitinib →
Severe Alopecia →

Recent signals(4)

ClinicalAugust 4, 2026

Real-world study on Ritlecitinib for severe Alopecia Areata reveals patient and dermatologist insights

The study analyzes real-world data on ritlecitinib use in severe alopecia areata, focusing on patient demographics and treatment satisfaction.

Clinical
July 27, 2026

Ruxolitinib Trial for APECED-Associated Alopecia Areata Underway

A clinical trial is evaluating the efficacy and safety of ruxolitinib for hair regrowth in patients with APECED-associated alopecia areata.

ClinicalJuly 25, 2026

Eli Lilly's LY4005130 Trial for Severe Alopecia Areata Underway

Eli Lilly is conducting a trial to evaluate the efficacy and safety of LY4005130 in adults with severe alopecia areata.

ClinicalJuly 3, 2026

Sun Pharma initiates trial for deuruxolitinib in severe alopecia areata in Japan

A clinical trial is underway to assess deuruxolitinib's efficacy and safety in Japanese adults with severe alopecia areata.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.